Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology Forecast 2025-2034

Mannose phosphate isomerase (MPI) deficiency is an ultra-rare congenital disorder, affecting fewer than 1,000 individuals in the United States, with early infancy onset and multisystem involvement.

Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology Forecast Report Coverage

Expert Market Research's “Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of mannose phosphate isomerase (MPI) deficiency. It projects the future incidence and prevalence rates of mannose phosphate isomerase (MPI) deficiency cases across various populations. The study covers age, gender, and type as major determinants of the mannose phosphate isomerase (MPI) deficiency population. The report highlights patterns in the prevalence of mannose phosphate isomerase (MPI) deficiency over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of mannose phosphate isomerase (MPI) deficiency in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Mannose Phosphate Isomerase (MPI) Deficiency Understanding: Disease Overview

Mannose phosphate isomerase (MPI) deficiency, also known as congenital disorder of glycosylation type Ib (CDG-Ib), is an ultra-rare autosomal recessive metabolic disease. It stems from pathogenic variants in the MPI gene, causing defective N-glycosylation of proteins. Patients present with hepatic fibrosis, coagulopathy, gastrointestinal bleeding, and hypoglycemia, while neurologic function is usually preserved. The disorder often manifests in infancy or early childhood, but diagnosis may be delayed due to nonspecific symptoms. Confirmation relies on biochemical assays and MPI gene sequencing.

Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology Perspective

The mannose phosphate isomerase (MPI) deficiency epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for mannose phosphate isomerase (MPI) deficiency epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for mannose phosphate isomerase (MPI) deficiency and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Mannose phosphate isomerase (MPI) deficiency (MPI-CDG) is an ultra-rare congenital disorder, with fewer than 60 cases reported globally as of 2022.
• The majority of mannose phosphate isomerase (MPI) deficiency patients present with symptoms in early infancy or childhood, typically under 2 years of age.
• Both males and females are affected, with a reported cohort of 15 males and 28 females, showing no significant gender predilection.

Country-wise Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology

The mannose phosphate isomerase (MPI) deficiency epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, mannose phosphate isomerase (MPI) deficiency is an ultra-rare congenital disorder of glycosylation, with fewer than 1,000 diagnosed cases. Patients typically present with multisystem involvement, including gastrointestinal, hepatic, and endocrine abnormalities, while neurological development is generally preserved. Most cases manifest in early infancy or childhood, usually under 2 years of age. Early recognition is critical, as treatment with oral mannose supplementation has demonstrated significant clinical improvement in affected individuals.

Mannose Phosphate Isomerase (MPI) Deficiency: Treatment Overview

MPI deficiency is among the few treatable congenital disorders of glycosylation. Oral mannose supplementation bypasses the enzymatic defect, restoring normal glycosylation and reversing hepatic and gastrointestinal symptoms. Early diagnosis and prompt mannose therapy can prevent severe complications. Supportive care includes liver function monitoring, nutritional management, and management of coagulation abnormalities. Liver transplantation may be considered in refractory hepatic failure. Continuous research explores optimized dosing and long-term metabolic outcomes to enhance survival and quality of life in affected patients.

Key Questions Answered

• What are the key findings of mannose phosphate isomerase (MPI) deficiency epidemiology in the 8 major markets?
• What will be the total number of patients with mannose phosphate isomerase (MPI) deficiency across the 8 major markets during the forecast period?
• What was the country-wise mannose phosphate isomerase (MPI) deficiency epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of mannose phosphate isomerase (MPI) deficiency patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of mannose phosphate isomerase (MPI) deficiency during the forecast period of 2025-2034?
• What are the currently available treatments for mannose phosphate isomerase (MPI) deficiency?
• What are the disease risks, signs, symptoms, and unmet needs of mannose phosphate isomerase (MPI) deficiency?

Scope of the Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of mannose phosphate isomerase (MPI) deficiency based on several factors.
• Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The mannose phosphate isomerase (MPI) deficiency report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.